For Research Use Only. Not for Human Consumption.
Recorded market$95.17Recorded exact-size market estimate: 95.17 USD for one 5 mg container (19.034136 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$95.00Member price$59.9037% lessMembers save $35.27 on this item vs. recorded market
Long-acting amylin analog for metabolic research.
Exact-size price research
Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. This reference uses recorded prices for the same 5 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$11.98/mg37% less
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 04:30 UTC. 1 x 5 mg = 5 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Simon’s Compounding Oct 10, 2026 UTC | One 5 mg container; 180.00 USD | $36.00/mg | powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| Pure Lab Peptides Oct 10, 2026 UTC | One 5 mg container; 79.99 USD | $16.00/mg | powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| MyGLP1Store Oct 11, 2026 UTC | One 5 mg container; 69.00 USD | $13.80/mg | powder; In stock Price observation; no COA authentication is implied by inclusion. |
| Regentide Oct 10, 2026 UTC | One 5 mg container; 144.99 USD | $29.00/mg | powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| Direct Doctor Supply Oct 11, 2026 UTC | One 5 mg container; 99.00 USD | $19.80/mg | powder; Coming soon; not orderable Price observation; no COA authentication is implied by inclusion. |
| Expert Peptides Oct 11, 2026 UTC | One 5 mg container; 89.99 USD | $18.00/mg | powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| Santa Cruz Peptides Oct 11, 2026 UTC | One 5 mg container; 70.00 USD | $14.00/mg | powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| CellPeptides Oct 11, 2026 UTC | One 5 mg container; 68.00 USD | $13.60/mg | powder; available Price observation; no COA authentication is implied by inclusion. |
| Peptide Aus Oct 11, 2026 UTC | One 5 mg container; 129.99 AUD | $18.15/mg | powder; in stock Price observation; no COA authentication is implied by inclusion. |
| Peptides Optimized Oct 11, 2026 UTC | One 5 mg container; 59.99 USD | $12.00/mg | powder; in stock Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “Cagrilintide – 5 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/cagrilintide-5-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/cagrilintide-5-mg/
A long-acting amylin analog investigated in preclinical research on satiety signaling and energy intake regulation.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
Cagrilintide is a long-acting amylin analogue investigated for weight management. Unlike many compounds in peptide catalogs, it has randomized human outcome data. Those data still require careful attribution: cagrilintide alone and its combination with semaglutide are different interventions.
Amylin-related signaling and GLP-1-related signaling are different. Semaglutide is the separate GLP-1 component of the combination commonly called CagriSema.
A study-manufactured intervention with controlled dosing, follow-up and eligibility criteria is not automatically equivalent to a catalog vial or an independently assembled blend.
The 2021 phase 2 trial supports a weight-management signal for cagrilintide alone in adults with overweight or obesity without diabetes. The 2025 REDEFINE 1 trial provides larger, longer evidence for the coadministered combination. Its headline result must not be described as the effect of cagrilintide alone.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Randomized phase 2 dose-finding study in 706 adults, with placebo and liraglutide comparison groups Reading scope: PubMed abstract and bibliographic record; not full-text review |
At 26 weeks, cagrilintide groups had greater mean weight reduction than placebo; gastrointestinal events were more frequent. | Results varied by study group and estimand. The controlled population and treatment setting limit application to other populations or products. |
| Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Phase 3a randomized 68-week REDEFINE 1 trial in 3,417 adults without diabetes Reading scope: PubMed abstract and bibliographic record; not full-text review |
The cagrilintide–semaglutide group had an estimated mean weight change of −20.4% versus −3.0% with placebo under the treatment-policy estimand. | This result belongs to the combination. It is not a cagrilintide-only result, and it includes a specific trial population and lifestyle intervention. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
An estimand defines which treatment question the analysis answers, including how it handles stopping or not adhering to treatment. A percentage assuming continued adherence should not be presented as identical to an intention-to-treat-style estimate.
The REDEFINE 1 abstract describes separate monotherapy arms, but the quoted primary comparison is combination versus placebo. A comparison against cagrilintide alone needs the corresponding arm data rather than subtraction or guesswork.
Weight reduction does not by itself establish an effect on every cardiovascular, metabolic or longevity outcome. Each additional claim needs its own measured endpoint.
In the phase 2 study, nausea and other gastrointestinal events were frequent. In REDEFINE 1, gastrointestinal events occurred more often with the combination than placebo, although most were described as transient and mild to moderate.
The combination adverse-event rate cannot isolate which component caused an event or predict the safety of an independently sourced mixture.
Dose-finding and escalation were parts of monitored trial protocols. They should not be repurposed as a personal titration plan or instructions for combining substances.
Keep monotherapy and combination exposures in separate rows. A total blend mass does not specify the amount of either component or establish equivalence to the coadministered trial regimen.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Verify whether a listing is single-agent cagrilintide or a declared mixture, with the amount and identity of every component clearly stated.
A percentage purity result alone cannot verify correct content, stability or equivalence to trial material. This article does not establish current local authorization or commercial availability of a product.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. The quoted REDEFINE 1 result is for coadministered cagrilintide and semaglutide, alongside lifestyle intervention, in adults meeting trial criteria.
No. Clinical evidence and product identity are separate. Trial results do not authenticate the sequence, amount, handling or formulation of a particular listing.
This companion to the Cagrilintide research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
Dose-finding and escalation were parts of monitored trial protocols. They should not be repurposed as a personal titration plan or instructions for combining substances.
Keep monotherapy and combination exposures in separate rows. A total blend mass does not specify the amount of either component or establish equivalence to the coadministered trial regimen.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.